Aifa approva la rimborsabilità della nuova formulazione in compresse di un farmaco mirato
Risultati per: Gestione della diverticolite del colon
Questo è quello che abbiamo trovato per te
Sviluppato un test del sangue per la diagnosi del tumore al colon
New England, prove da uno studio su 8000 individui
Tumore colon, con le nuove tecniche chirurgiche -50% complicanze
Conseguenze più gravi in 10%casi,costo per Ssn fino 100mila euro
Three-dimensional imaging of the enteric nervous system in human pediatric colon reveals new features of Hirschsprung disease
Hirschsprung disease is defined by the absence of enteric nervous system (ENS) from distal bowel. Primary treatment is “pull-through” surgery to remove bowel that lacks ENS with re-anastomosis of “normal” bowel near the anal verge. Problems after pull-through are common and some may be due to retained hypoganglionic bowel (i.e., low ENS density). Testing this hypothesis has been difficult because counting enteric neurons in tissue sections is unreliable even for experts. Tissue clearing and 3-dimensional imaging provides better data about ENS structure than sectioning.
Linee guida sulla valutazione e gestione della malattia renale cronica
Tumore colon-retto, screening è salvavita fino al 90% dei casi
Survey Aigo, “al centro-nord performance più elevate”
Linee guida sulla diagnosi e gestione del cancro al polmone
Linea guida sulla gestione della pancreatite acuta
Carenza di vitamina B12: diagnosi e gestione
Tumore al colon retto e sindrome di Lynch, con la biopsia liquida diagnosi tempestiva
E’ una condizione genetica ereditaria che aumenta il rischio di malattia oncologica
Diagnosi e gestione iniziale dell’ipertensione
Gestione integrata del diabete in Piemonte: modello virtuoso tra medici di base e specialisti
Attivo da anni, il percorso culturale, organizzativo e istituzionale ha fatto registrare risultati positivi sia dal punto di vista terapeutico sia sulla spesa sanitaria
Linee guida cliniche sulla gestione dell’obesità
Via al Master 2/o livello “Gestione clinica cardiomiopatie”
Cardiologia dell’Università degli Studi di Trieste
Via al Master 2/o livello “Gestione clinica cardiomiopatie”
Cardiologia dell’Università degli Studi di Trieste
Fibre-rich Foods to Treat Obesity and Prevent Colon Cancer trial study protocol: a randomised clinical trial of fibre-rich legumes targeting the gut microbiome, metabolome and gut transit time of overweight and obese patients with a history of noncancerous adenomatous polyps
Introduction
Recently published studies support the beneficial effects of consuming fibre-rich legumes, such as cooked dry beans, to improve metabolic health and reduce cancer risk. In participants with overweight/obesity and a history of colorectal polyps, the Fibre-rich Foods to Treat Obesity and Prevent Colon Cancer randomised clinical trial will test whether a high-fibre diet featuring legumes will simultaneously facilitate weight reduction and suppress colonic mucosal biomarkers of colorectal cancer (CRC).
Methods/design
This study is designed to characterise changes in (1) body weight; (2) biomarkers of insulin resistance and systemic inflammation; (3) compositional and functional profiles of the faecal microbiome and metabolome; (4) mucosal biomarkers of CRC risk and (5) gut transit. Approximately 60 overweight or obese adults with a history of noncancerous adenomatous polyps within the previous 3 years will be recruited and randomised to one of two weight-loss diets. Following a 1-week run-in, participants in the intervention arm will receive preportioned high-fibre legume-rich entrées for two meals/day in months 1–3 and one meal/day in months 4–6. In the control arm, entrées will replace legumes with lean protein sources (eg, chicken). Both groups will receive in-person and written guidance to include nutritionally balanced sides with energy intake to lose 1–2 pounds per week.
Ethics and dissemination
The National Institutes of Health fund this ongoing 5-year study through a National Cancer Institute grant (5R01CA245063) awarded to Emory University with a subaward to the University of Pittsburgh. The study protocol was approved by the Emory Institutional Review Board (IRB approval number: 00000563).
Trial registration number
NCT04780477.